Innovation

Our Q2 2024 sales and earnings report

July 30, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Merck’s (NYSE: MRK) Q2 2024 results demonstrate strong business momentum and further progress in our diverse pipeline. Our company announced worldwide sales of $16.1 billion, an increase of 7% from Q2 2023.

“Our business is demonstrating strong momentum as we exit the first half of the year,” said Rob Davis, chairman and chief executive officer. “Through excellent scientific, commercial and operational execution, we’re achieving significant milestones for our company and for patients. I am proud of our dedicated teams around the world that are working tirelessly to advance our deep pipeline as we continue delivering innovation that solves unmet medical needs.”​

Merck anticipates full-year 2024 worldwide sales to be between $63.4 billion and $64.4 billion. ​

Find more details on Q2 2024 results below.

infographic

Download infographic

Innovation

What is One Pipeline?

How we’re advancing the best internal and external science to progress our pipeline for patients

May 30, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Men and women sitting around conference room table talking

Drug development is a long and difficult endeavor. It can take more than 10 years to bring a new medicine to market. So how does our company think about developing new medicines and vaccines to help save and improve lives? The answer: through our One Pipeline strategy, where we complement our internal innovation and discovery efforts with the best external science through business development.

Dean Li

“Our One Pipeline strategy enables us to advance breakthrough science, whether it comes from our own labs or from our partners’ labs, and make medicines and vaccines for patients,” said Dr. Dean Li, president, Merck Research Laboratories (MRL). “Every day, we’re pushing scientific boundaries in research. Business development and external partnerships are integral to help drive our internal pipeline and to provide access to assets that are important for our discovery and clinical development groups.”

To achieve that balance, MRL works in lockstep with our business development and licensing (BD&L) team. “I want to emphasize how integrated BD&L is with MRL. This is hand in glove,” said Li.

Business development augments our pipeline

Our BD&L team is committed to securing scientific and commercial collaborations, licensing agreements and acquisitions from discovery to late-stage candidates and new technologies to help build our robust portfolio. We have a legacy of successful collaborations and are among the most active dealmakers in the biopharma industry.

“We match our strong scientific conviction with bold investments in novel, cutting-edge science to advance new options for patients,” said Sunil Patel, senior vice president, head of corporate development and BD&L. “We’re focused on bringing in the best external science to complement our internal efforts to deliver on our purpose and sustain our company for the next 130 years.”

~$50B

Invested towards business development since 2019.

~80

Significant transactions executed annually across technologies, modalities, therapeutic areas and phases of development.

The BD&L team members focused on our pipeline are embedded with scientists across our research network and, in addition to our New Jersey and Pennsylvania sites, they’re strategically located in key epicenters of innovation including Boston, Cambridge, London, South San Francisco, Shanghai and Tokyo. The team searches the globe for cutting-edge science and works alongside our research team to evaluate opportunities built on strong scientific principles, regardless of location or origin.

Creating a sustainable innovation engine

two scientists in a lab

As part of our One Pipeline strategy, we ensure a smooth transition when bringing in external science and leverage our clinical development and manufacturing expertise to advance each program with speed and rigor. This strategy is helping to build and maintain the flow of novel candidates through clinical development to patients, enabling long-term, sustainable growth for our company.

“Strategic business development focused on the best external science remains an important priority for our company. We’ve demonstrated that we can leverage our deep discovery prowess to identify important acquisition targets and then add significant value through our powerful clinical research engine, our regulatory expertise and our commercial scale, which together can serve to accelerate development and enable broad global access to important medical discoveries for patients in need,” said Rob Davis, chairman and chief executive officer.

lab

Pipeline

We’re focused on discovering new medicines and vaccines for today and the future. View our pipeline.

people in a business meeting

Business development and licensing

We work with many partners, from early-stage science to clinical-stage programs, to deliver life-changing therapies. Learn more.

Innovation

Vaccine inventors, creators and innovators

Dr. Maurice Hilleman was among the pioneering scientists who made strides in vaccine history and the fight against infectious disease

May 8, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

vaccine-history-maurice-hillman

Dr. Maurice Hilleman, who led our department of virus and cell biology from 1957 to 1984.

When were vaccines invented?

The story of modern day vaccines began in 1796 when Dr. Edward Jenner inoculated 9-year-old James Phipps with cowpox as a way to protect him from smallpox. The term ‘vaccine’ is later coined, taken from the Latin word for cow, vacca. Smallpox was the first disease people tried to prevent by intentionally inoculating themselves with infected matter.

Dr. Edward Jenner inoculating 8-year-old James Phipps with cowpox

Dr. Edward Jenner inoculating 9-year-old James Phipps with cowpox.

Eight decades after Jenner published his findings, Louis Pasteur developed the first live attenuated rabies vaccine. Attenuation is a process that weakens the bacteria or virus in a vaccine so it’s less likely to cause disease, while still triggering an immune response similar to the natural infection. During the mid- to late-20th century, advances in basic and clinical research made it possible for scientists to develop vaccines to help protect against both bacterial and viral diseases.

Dr. Maurice Hilleman’s contribution to vaccine development

The names Jonas Salk and Albert Sabin have become synonymous with their inventions and developments around the polio vaccine, and the giant strides they made in the fight against viral diseases. Although these are some of the most famous names in vaccine research, Merck has a legacy of vaccine pioneers, too. Dr. Maurice Hilleman, who led Merck’s department of virus and cell biology from 1957 to 1984, also belonged to that distinguished group. Credited with helping to develop more than 40 experimental and licensed human and animal vaccines, Hilleman’s passionate commitment continues to inspire scientists in medical research laboratories to this day.

Hilleman was born and raised on a farm in Montana. It was a hard life, but a farm background was a great foundation for his later work.

“When you’re brought up on a farm, you have a lot of general knowledge,” he said. After graduating from the University of Chicago with a doctorate in microbiology and chemistry, Hilleman chose to work at a pharmaceutical company instead of academia.

Despite his many accomplishments, including helping to develop more than 40 human and animal vaccines, Hilleman’s name is virtually unknown by the general public and press. Yet his impact on public health is undeniable.

“His commitment was to make something useful and convert it to clinical use. Maurice’s genius was in developing vaccines, reliably reproducing them, and he was in charge of all pharmaceutical facets from research to the marketplace.”

  • Dr. Paul Offit
    Director of the Vaccine Education Center, professor of pediatrics in the Division of Infectious Diseases at Children’s Hospital of Philadelphia, and Hilleman’s biographer

In 1988, President Ronald Reagan awarded Hilleman the National Medal of Science, and in 1997, he was honored with the Albert B. Sabin Gold Medal Award. Dr. Anthony Fauci, former director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, called Hilleman “one of the true giants of science, medicine and public health in the 20th century.”

Innovation

Vaccines: Our history, our legacy

We've been working to discover and develop vaccines for more than a century

May 8, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

healthcare working putting a bandaid on a child's arm

“An epidemic of diphtheria is almost inevitable here. Stop. I am in urgent need of one million units of diphtheria antitoxin. Stop. Mail is only form of transportation. Stop.”

  • Dr. Curtis Welch

This was the desperate radio telegram in January 1925 from Dr. Curtis Welch in Nome, Alaska, to all the major Alaska towns, to territorial governor Scott Bone in Juneau, and to the U.S. Public Health Service in Washington, D.C. Diphtheria was spreading through the icebound community. Children had already died, and the local supply of diphtheria antitoxin had expired the previous summer.

Known as the “Great Race of Mercy,” it’s an iconic story of human compassion.

dog sled background image

Weather prevented delivery by air, so relay teams of sled dogs and their mushers raced against the clock to deliver 300,000 units of antitoxin, which was produced by Merck legacy company H.K. Mulford. They completed the 674-mile journey over what later became known as the Iditarod Trail in a record-breaking five days and seven hours despite whiteout conditions and temperatures of 50 degrees below zero.

dog sled alaska
icon
674 miles
icon
5 days
icon
300,000 units

Over 130 years of vaccine leadership

In 1895, the H.K. Mulford Company began marketing the first commercially available diphtheria antitoxin in the U.S., the very medication that helped avert the diphtheria epidemic in Nome. Today, we have a significant presence in vaccine discovery, development and distribution in both human and animal health.

Dr. Maurice Hilleman

The vaccine pioneers

Merck’s Dr. Maurice Hilleman belongs to a distinguished group of vaccine pioneers — including Edward Jenner, Louis Pasteur, Jonas Salk and Albert Sabin. Hilleman is credited with helping to develop more than 40 vaccines and his impact on public health is undeniable.

Vaccines are not just for children

The U.S. Centers for Disease Control and Prevention consider vaccines to be one of the 10 great public health achievements of the 20th century. In the U.S., vaccines are now available for a number of infectious diseases that once routinely affected people. While there are many vaccines available for children, it’s important to remember that adults also are susceptible to vaccine-preventable infectious diseases.

Each year in the U.S., thousands of adults suffer complications from these diseases. In low- and middle-income countries the toll is even higher.

Innovation

Our Q1 2024 earnings report

April 25, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023.

“Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing the impact of our broad commercial portfolio for the benefit of patients,” said Rob Davis, chairman and chief executive officer. “We drove strong growth across key therapeutic areas, executed strategic business development, and in the U.S., we are now launching WINREVAIR, a significant new product in the cardiometabolic space for adults with pulmonary arterial hypertension, a progressive and debilitating disease. We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them.”

Merck anticipates full-year 2024 worldwide sales to be between $63.1 billion and $64.3 billion.

Take a look at the infographic below for more details on Q1 2024 results.

Download infographic

1Q infographic
Innovation

A new foundation for future talent

We’re partnering with N.C. A&T to launch a collaborative biotechnology learning center

April 22, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Building the workforce of tomorrow means investing in the students of today. That’s why we’ve partnered with North Carolina Agricultural and Technical State University (N.C. A&T) — the largest historically Black college and university in the U.S. — to launch the Merck Biotechnology Learning Center.

“We’re pleased to launch this new collaboration with an institution that precisely aligns to our company priorities to invest in the growth and delivery of innovative health solutions and strong values around diversity and inclusion,” said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. “Together we can fuel the growth of talent for our company and the biotechnology industry overall.”

Located in the home state of our Durham and Wilson manufacturing sites, the 4,025 square-foot facility will enhance academic programming and training for biotechnology careers for N.C. A&T students and provide advanced discovery opportunities through its classroom space, process laboratory and state-of-the-art biopharmaceutical manufacturing equipment.

“This collaboration signifies a union between academia and industry, and a commitment to excellence, innovation and the advancement of scientific knowledge,” said Tonya Smith-Jackson, Ph.D., provost and executive vice chancellor of academic affairs for N.C. A&T.

The collaboration also signifies an investment in the community’s future by expanding local and statewide bioeconomy initiatives. It’ll also help to expand talent and recruitment opportunities for our company and offer vaccine manufacturing process training for new and existing employees. 

“The Merck Biotechnology Learning Center will provide opportunities for N.C. A&T students to look inside the biopharmaceutical industry and understand what a career in this space looks like. Through our joint initiative with N.C. A&T, we’re developing new and innovative ways to build a pipeline of talent here in North Carolina and beyond.” 

  • Amanda Taylor
    Vice president and Durham plant manager
Innovation

Humans, animals and the environment – our health is all connected

Why the One Health approach is important now more than ever

April 15, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

little girl hugging a white dog

The health of humans, animals and the environment are all interconnected. When the health of one is at risk, the health of all may be at risk.   

We see it in diseases transferred between animals or insects and humans (called zoonotic and vector-borne diseases) such as rabies, Lyme disease, West Nile virus, swine flu and Ebola, among others. We also see it in the growing threat from antimicrobial resistance (AMR), which occurs when bacteria mutate in ways that make the medicines (antimicrobials) used to treat infections ineffective, or when these medicines are used inappropriately to treat viral infections. Or, in diseases in food-producing animals, jeopardizing global food security.

Our increasing vulnerability to such new health challenges has led to a focus on “One Health” — an integrated approach to addressing human, animal and environmental health for the benefit of all.

What is One Health?

One Health is the collaborative approach across multiple disciplines — working locally, regionally, nationally and globally — to prevent, detect and respond to health issues at the interfaces between humans, animals and the environment.

illustration of lots of people working together

It requires collaboration among doctors, veterinarians, nurses, public health practitioners, epidemiologists, agricultural workers, ecologists, wildlife experts, and industry as well as policymakers, communities and even pet owners.

“No one person, organization or sector can address these issues alone. Identifying and responding to growing health challenges requires teamwork,” says Holger Lehmann, DVM, Ph.D., VP, pharmaceuticals research and development, Merck Animal Health.

But what has led to these increasing population health threats?

Why are we more vulnerable to new health challenges?

Society has undergone major changes over the past century. While technology, increased mobility, industrialization, urbanization and globalization have advanced human, animal and environmental health in many ways, they’ve also made us more vulnerable to new health challenges.

For example, according to the Centers for Disease Control and Prevention, every year, millions of people and animals around the world are affected by zoonotic diseases. Scientists estimate that around 60% of emerging infectious diseases that are reported globally come from animals, both wild and domestic. Over 30 new human pathogens have been detected in the last 3 decades, 75% of which have originated in animals.

They can be spread in a number of ways, including direct or indirect contact, vector-borne, foodborne or waterborne. In fact, foodborne pathogens cause millions of cases of sporadic illness and chronic complications, as well as large and challenging outbreaks in many countries and between countries.

In addition, increased exposure to new viruses/bacteria combined with excessive and/or inappropriate use of medicines is causing a rise in AMR. Worldwide, an estimated 4.95 million people died with drug-resistant bacterial infections in 2019, and 1.27 million of these deaths were directly caused by antimicrobial resistance (AMR).

Three main factors are fueling these population health threats, increasing the probability and speed of spreading diseases. They are:

farmland landscape with livestock

Changes in climate and land use

Deforestation and other disruptions in environmental conditions can provide new opportunities for diseases to develop.

Exponential population growth and expansion into previously uninhabited areas

More people are living in close connection to their companion animals, and in some cases, closer to wild and domestic animals.

world map with lines showing increasing mobility

Increased international mobility

People, animals and animal products are moving more frequently, easily and widely than ever before.

Our commitment to One Health

With deep expertise in both human and animal health and a commitment to our shared environment, our company is well-positioned to be a leader in the One Health approach.

“We recognize the issues — such as zoonotic and infectious diseases and food safety and security — are interrelated,” says Ian Tarpey, Ph.D., VP, biological research and development, Merck Animal Health. “Our Animal Health and Human Health teams will continue to collaborate to discover and develop preventative solutions for existing and emerging diseases in animals and people.”

Our One Health approach focuses on many areas, including:

icon
Disease prevention

We remain focused on discovering and developing vaccines and technologies to help prevent both human and animal diseases.

icon
Surveillance and monitoring

We’re committed to advocating for and participating in scientifically based surveillance monitoring systems to better understand, track and predict health-related issues.

icon
Respecting our environment

We support science-based, environmentally sound international and national programs to address the challenges to environmental health.

icon
Innovation

Our human and animal health research laboratories collaborate in antimicrobial and vaccine research in many ways including sharing enabling technologies, expertise and evaluation of external opportunities. We’re also investing and developing predictive, monitoring and diagnostic technologies to help animal caretakers make data-driven evaluations of an animal’s health status and optimize their animals’ health and well-being.

icon
Stewardship of essential medicines

We’re playing a leading role in addressing AMR by not only discovering and developing medicines and vaccines to treat and prevent infectious diseases in humans and animals but also supporting responsible use of these products.

icon
Safe and sustainable food supply

We continue to work on developing vaccines and other tools to prevent animal disease to ensure a safe, nutritious, sustainable food supply, and we’ve implemented surveillance initiatives to enable more accurate risk profiling, early disease detection and individualized diagnosis/treatment decisions in livestock.

two dogs running on the grass

The science of healthier animals

We build strong partnerships in an effort to improve the health of animals around the world, and approach our work with a deep sense of responsibility — to our customers, consumers, animals, society and the planet.

Our work to promote optimal health continues

“One Health recognizes the interconnectedness of human, animal and environmental health, acknowledging that the well-being of each is intricately linked. By embracing a collaborative approach, we can effectively address the complex challenges and promote optimal health for both humans and animals.”

– Dr. Jenelle Krishnamoorthy, VP, global public policy

Innovation

Taking on Zaire ebolavirus

How science and innovation fuel our efforts to help combat a rare but potentially deadly disease

April 11, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Taking on Ebola

Patients inspire us to pursue the best science in our inventions and everything we do. Every innovation has the potential to help build a healthier, more hopeful future for people everywhere — which means taking on some of today’s global health challenges, including Ebola.

Leading the effort to combat Zaire ebolavirus

Our company is a health care leader in the fight against Zaire ebolavirus. Along with external collaborators from all sectors, our scientists are at the forefront of the response to outbreaks of this potentially deadly disease as we continue to help address this global health challenge. Zaire ebolavirus has had a devastating impact on the world and has proved itself to be a potentially deadly and contagious disease, with a survival rate of 50%. While there are six identified Ebola virus species, the Zaire ebolavirus strain has been the leading cause of outbreaks over the last 20 years.

Global public health preparedness against future Zaire ebolavirus outbreaks requires advanced planning, system readiness for rapid deployment and collaboration and partnership between public and private entities around the world. Our partnerships with the World Health Organization (WHO) and other health partners around the globe are a crucial component of our commitment to helping save and improve lives.

“We take Zaire ebolavirus outbreaks very seriously and act with the utmost urgency to support response efforts,” said Rachael Bonawitz, clinical director, clinical research vaccines. “Our teams are dedicated to supporting the frontline workers whose brave actions are critical in outbreak response efforts.”

In 2021, we established an agreement with UNICEF to create the world’s first global Ebola Zaire stockpile, the result of breakthrough innovation and collaboration with four leading international health and humanitarian organizations across the world. The global stockpile offers a critical, rapid-response tool.

“It has been our honor to collaborate with WHO, Gavi, UNICEF, the U.S. government and many others in supporting outbreak preparedness and response efforts,” said Drew Otoo, president of global vaccines. “Through these collaborations, we demonstrate what’s possible when partners come together to pursue a common purpose for patients.”

This level of collaboration continues to be needed for Zaire ebolavirus and other diseases. We remain committed to working in collaboration with global and local health partners to support current and future outbreak response efforts.

Innovation

Teaming up with Eisai to help fight cancer

How we're leveraging each other’s unique strengths to help advance cancer research

April 10, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientists wearing masks working in a lab

Combining two ambitious cancer research teams to form a united front to help people with cancer

It’s sometimes said that the whole is greater than the sum of its parts. That’s why in 2018 we teamed up with Eisai, a global pharmaceutical company headquartered in Japan, to work together to advance cancer research.

“Combining Merck’s leadership in immuno-oncology with Eisai’s strengths in small molecules allows us to advance a combination approach that has the potential to help more people living with challenging cancers,” says Dr. Gregory Lubiniecki, vice president, global clinical development, Merck Research Laboratories.

Dr. Takashi Owa

"There's still an unmet need for many patients with cancer. These patients and their families are in need of more treatment options, and this remains at the forefront of our collaborative efforts."

Dr. Takashi Owa

Vice president, chief medicine creation and chief discovery officer, oncology business group, Eisai

Together, we’re striving to drive cancer science forward, and this shared vision has led to multiple clinical trials investigating the companies’ combination treatment option in various tumor types.

Through this comprehensive approach, we’ve been expanding the joint clinical program to help as many cancer patients as possible.

Why did you decide to go into oncology research?

“My decision was very personal,” says Owa. “At the age of six, my grandmother passed away from gastric cancer. I couldn’t fully process what had happened to her at that young age. It wasn’t until I entered junior high school that I began to understand the toll cancer had taken on her, which motivated me to learn about cancer and find my passion in cancer research.”

Lubiniecki’s experience was also very personal.

“Watching my mother recover from breast cancer while I was in high school exposed me to the challenges patients face when battling cancer. These experiences inspired me to ultimately pursue oncology,” explains Lubiniecki. “Oncology clinical research offers an opportunity to impact the practice of medicine greatly.”

Looking to the future

“I’m proud of what we’ve been able to accomplish together in our pursuit to investigate additional options for patients across a broad range of cancer types through our robust clinical development program,” says Lubiniecki.

Owa is optimistic about the progress the two teams have made together. “We’ve already seen encouraging anti-tumor activity in several difficult-to-treat cancers, which has led to multiple milestones to date,” he says. “As we continue to enhance our knowledge and scientific evidence through our ongoing clinical research efforts, together, we aim to give patients and their families hope.”

Lubiniecki believes that collaborations are important to continuing to advance cancer research and improve the outcomes of people with cancer.

Dr. Greg Lubiniecki smiling

“A collaborative approach is key to advancing science and making strides in drug discovery and development.”

Dr. Gregory Lubiniecki

Vice president, global clinical development, Merck Research Laboratories

“Working with others driven by the same patient-centric goals can yield innovations and is imperative to continued progress in improving patient care,” says Lubiniecki. “I’m thrilled to be a part of this collaboration as we continue to advance and expand the clinical trial program.”

Innovation

How Merck scientists are driving next-generation cancer research

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth

March 29, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

collage of photos of scientists working in labs

In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease — scientists have classified hundreds of types and found a myriad of genetic drivers underlying them. This means, just as cancer isn’t one disease, there cannot be just one way to treat all cancers.

“We’ve witnessed dramatic progress in how we treat a wide range of cancers, and our work at Merck has been foundational in how we treat metastatic disease, or cancer that has spread.”

  • Dr. Jane Healy
    Vice president and head of oncology early development, Merck Research Laboratories

“This is just the tip of the iceberg. These advancements are helping to fuel the next generation of discoveries and drive progress in the way we care for people with all stages of cancer. We must push research forward that supports early discoveries and novel innovations to advance the future of cancer research,” Healy said.

Driving research toward treating certain cancers earlier

With the ultimate goal of providing patients with the greatest chance for survival, our researchers are building a broad clinical development program focused on treating certain cancers at earlier stages.

“Expanding our research efforts into earlier stages of disease remains a top priority,” said Healy. “We’re pursuing research where we have the greatest potential to make a significant impact in helping reduce the risk of recurrence and improving survival.”

A robust pipeline of diverse approaches to advanced and earlier stages of cancer

In addition to driving research in earlier stages of cancer, Healy and her colleagues are investigating multiple mechanisms and modalities that may have the potential to address cancer in innovative ways. Through our own research and external collaborations, we’ve developed a robust pipeline that encompasses diverse approaches to treating advanced and earlier stages of cancer across more than 20 novel mechanisms, including:

  • Boosting anti-tumor immune responses: Learnings from recent advancements in cancer care have informed a more focused approach to research. Now, we’re investigating foundational cancer treatments combined with negative immune regulators that play different roles in adjusting the immune response.

    We’re also exploring individualized neoantigen therapies, a growing area of research focused on sharpening the immune response against a person’s own tumor by developing a therapy unique to their tumor’s mutation.
  • Tissue-specific targeting of chemotherapy to increase cancer cell sensitivity to immune responses: While chemotherapy remains an important treatment option, our scientists are exploring how antibody-drug conjugates (ADCs), with novel chemotherapy-like payloads, can be used as a more targeted approach to deliver chemotherapy.

    Similarly, we’re pursuing research that enhances the ability of T cells to recognize and attack tumors.
  • Impacting pathways that can drive cancer growth: We’ve identified opportunities for the direct targeting of cancer cell vulnerabilities and transcription factors that were previously considered untreatable. By designing therapeutic candidates that inhibit or degrade proteins and genes implicated in cancer pathways, we’re evaluating new ways to help address rare and difficult-to-treat cancers that currently have limited treatment options.

"We're committed to investing in novel research where scientific opportunity and medical need converge. "

— Jane Healy

“These key areas of research are the cornerstones of our broad and diverse pipeline, with more than 2,250 ongoing clinical trials, which include more than 1,600 trials evaluating combination regimens. We remain dedicated to discovering new ways to fight this disease and optimizing existing approaches — all while continuing to lead in supporting the next generation of cancer research,” said Healy.

Learn more about our oncology pipeline